STOCK TITAN

Pharvaris to Participate in Upcoming March Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) announced participation in three investor conferences in March 2022. The events include:

  • BioCapital Europe 2022 on March 10, 2022, at 3:00 PM CET in Amsterdam.
  • Oppenheimer 32nd Annual Healthcare Conference via webcast on March 15, 2022, at 8:00 AM ET.
  • SVB Leerink Mountain Meeting on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.
A live audio webcast for the Oppenheimer conference will be available on the Pharvaris website.

Positive
  • None.
Negative
  • None.

ZUG, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in three upcoming investor conferences in March:

BioCapital Europe 2022
Format: Live In-Person Presentation
Date/Time: Thursday, March 10, 2022 at 3:00 PM CET (9:00 AM EST)
Location: Amsterdam, Netherlands

Oppenheimer 32nd Annual Healthcare Conference
Format: Webcasted Fireside Chat
Date/Time: Tuesday, March 15, 2022 at 8:00 AM ET
Location: Virtual

SVB Leerink Mountain Meeting
Format: Live In-Person Presentation
Date/Time: Tuesday, March 22, 2022, at 9:30 AM MT (11:30 AM ET)
Location: Jackson Hole, Wyoming

A live audio webcast of the Oppenheimer 32nd Annual Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the fireside chat.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

Pharvaris
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com

Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com

Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com


FAQ

What investor conferences is Pharvaris participating in March 2022?

Pharvaris will participate in the BioCapital Europe 2022, Oppenheimer 32nd Annual Healthcare Conference, and SVB Leerink Mountain Meeting.

When is the BioCapital Europe 2022 conference?

The BioCapital Europe 2022 conference is scheduled for March 10, 2022, at 3:00 PM CET.

How can I access the Oppenheimer conference webcast?

The Oppenheimer 32nd Annual Healthcare Conference webcast can be accessed through the Investors section of the Pharvaris website.

Where and when is the SVB Leerink Mountain Meeting?

The SVB Leerink Mountain Meeting will take place on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.

What is the focus of Pharvaris as a clinical-stage company?

Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema and other related conditions.

Pharvaris N.V. Ordinary Shares

NASDAQ:PHVS

PHVS Rankings

PHVS Latest News

PHVS Stock Data

993.01M
32.65M
9.49%
87.51%
0.25%
Biotechnology
Healthcare
Link
United States of America
Leiden